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Goodpasture’s disease is a rare autoimmune disorder characterised by the development of antiglomerular basement membrane
autoantibodies, which typically presents with rapidly progressive crescentic glomerulonephritis and pulmonary haemorrhage.
Even with aggressive nonspeciﬁc immunosuppression and plasma exchange, mortality remains high. We report a case of life-
threatening Goodpasture’s disease with relapsing pulmonary haemorrhage refractory to conventional therapy. Second line
treatment was based on mycophenolate mofetil 1g every 12 hours and prednisolone 60mg/day. In this case, the use of a low-
dose mycophenolate mofetil regimen turned out to be insuﬃcient. However, in our opinion higher mycophenolate mofetil doses
should be considered an alternative treatment, mainly in relapsing disease, due to its mechanism of action and current insuﬃcient
therapeutic weapons.
1.Introduction
Goodpasture’s disease is an autoimmune disorder charac-
terised by the development of autoantibodies to the NC1
domain of the α3 chain of type IV collagen, found in
glomerular, pulmonary, and other basement membranes.
Clinical presentation comprises rapidly progressive cres-
centic glomerulonephritis and pulmonary haemorrhage [1,
2]. It is an uncommon disease estimated to occur in
less than one case per million population [3]. Without
treatment it is a frequently fatal disease. Conventional
therapy is based on a combination of plasma exchange
withaggressivenonspeciﬁcimmunosuppressionandrelapses
are uncommon [4]. Despite this, mortality remains high,
with median time to death two months in patients with
pulmonary haemorrhage [5, 6]. We report a case of life-
threatening relapsing Goodpasture’s syndrome refractory to
conventional therapy which responded to treatment with
mycophenolate mofetil.
2.CaseReport
A 19-year-old man presented with cough and haemopty-
sis, evolving with severe anaemia, dyspnoea, haematuria,
and oliguric rapidly progressive renal failure three weeks
later. The patient had a history of smoking and had
inhaled cocaine weeks before the complaints onset. On
admission he was pale, with tachypnea, tachycardia, and
elevated blood pressure. Laboratory results revealed haema-
tocrit 20%; haemoglobin 7.0g/dL; blood urea nitrogen
81mg/dL; serum creatinine 7.4mg/dL; albumin 3.3g/dL
and potassium 4.6mmol/L. Complement components and
serum immunoglobulins were normal, antinuclear antibod-
ies, antiDNA antibodies, immune complexes, cryoglobulins,
and antineutrophil cytoplasmatic autoantibodies were nega-
tive while anti-GBM antibodies were positive. Chest X-ray
bilateral alveolar shadowing was indicative of pulmonary
haemorrhage. A renal biopsy specimen (Figures 1 and 2)
showed an extracapillary glomerulonephritis with cellular
crescents in ﬁve out of six glomeruli, mild diﬀuse interstitial
oedema, mild tubular atrophy, and vessels intact. Direct
immunoﬂuorescence showed linear deposit of IgG and
smaller amounts of C3 in all capillary loops of the six
glomeruli. Staining for IgA and IgM were negative. Electron
microscopy was not performed.
A diagnosis of Goodpasture’s syndrome was made
and treatment with oxygen, blood transfusion, once every
other day haemodialysis and plasmapheresis, with four2 International Journal of Nephrology
Figure 1: Light microscopy photograph (PAS: 250×): Circumfer-
ential cellular crescent with compressed capillary tuft.
litre exchanges and two units of fresh frozen plasma,
three 1g methylprednisolone boli, followed by prednisone
1mg/kg/day and cyclophosphamide 750mg/m2 of body
surface area bolus with a 75% adjustment for renal failure
(1000mg/pulse) initiated. The patient denied haemoptysis
or other respiratory symptoms after the second session
of plasmapheresis; pulmonary sounds were normal and
the anti-GBM antibodies titres became negative before the
eleventh session. A total of twelve sessions were completed
and the bolus of cyclophosphamide was repeated two weeks
after the previous dose. Serum creatinine levels remained
high, with mean predialytic value 7.1mg/dL, as he evolved
to anuria.
Threedaysafterthetwelfthplasmapheretictreatmentthe
patient began shortness of breath, cough with haemoptysis,
inspiratory rales and hypoxia. Fluid overload, restarting
smoking or other respiratory aggression were ruled out.
Coagulopathy was being prevented by the use of two units
of fresh frozen plasma at the end of each pheresis treatment.
Relapsing pulmonary haemorrhage with negative anti-GBM
antibodies, part of Goodpasture’s syndrome was assumed
and treatment resumed: another three day boli of 1g of
methylprednisolone and daily plasmapheresis with four litre
exchanges were started. After the two boli of cyclophos-
phamide (the last eleven days prior) it was decided to start
mycophenolate mofetil 500mg twice a day. On the second
daythecomplaintsceased,butonthesixthdayrecrudescence
of cough, haemoptysis, dyspnoea with hypoxaemic respira-
tory failure, and anaemia determined a brief intensive care
unit stay for surveillance. The mycophenolate mofetil dose
was doubled (1g every 12 hours), daily plasmapheresis and
oral prednisolone 1mg/kg/day were maintained. He evolved
with sustained recovery of pulmonary disturbances follow-
ing the second day of the increased mycophenolate dosage.
Despite favourable respiratory evolution, kidney function
was lost, as creatinine levels remained high (mean predialytic
value 6.7mg/dL), maintaining anuria and dependence upon
dialysis. This second course of plasmapheresis was stopped
after sixteen sessions and the patient was discharged with
resolution of lung haemorrhage and established chronic
renal failure.
After one year of followup and since the start of
the full dose of mycophenolate mofetil, no other episode
Figure 2: Immunoﬂuorescence microscopy photograph (IgG:
250×):LinearIgGdepositsinglomerularbasementmembranewith
Bowman capsule rupture.
of pulmonary haemorrhage has occurred, no pulmonary
permanent lesions were found six months after and anti-
GBM antibodies have been negative since the ﬁrst course of
plasmapheresis. The mycophenolate dose was decreased six
months later to 500mg every 12 hours, and steroid doses
slowly reduced to 5mg per day. As anti-GBM antibodies
remain undetectable this patient is now on the active waiting
list for renal transplant.
3. Discussion
Mycophenolate mofetil has been used since the 1990s as an
immunosuppressive drug for the prevention of rejection in
kidney transplantation. Due to favourable experience, with
fewer adverse eﬀects, it is currently used in liver, lung, and
bone marrow transplantation and in the treatment of several
autoimmune diseases, such as systemic lupus erythematosus,
systemic vasculitis [7, 8] and some primary glomerular
diseases [7, 9]. It suppresses the immune response by
inhibiting activated lymphocytes, blocks purine synthesis,
and inhibits speciﬁc proliferative responses of both T and
B cells to antigens [8, 10]. Its eﬀect on B cells can inhibit
humoral immune response and antibody production [11],
therefore stopping the autoimmune response to the trig-
gering event and preventing lesion cascade. Other proposed
mechanisms include the induction of apoptosis of activated
T lymphocytes and the inhibition of adhesion molecule
expression, which will lead to decreased recruitment of
lymphocytes and monocytes into sites of inﬂammation [12].
To our knowledge this is the second report of the use
of mycophenolate mofetil in the treatment of Goodpasture’s
syndrome [13]. Both cases had similar features of life-
threatening disease, were refractory to conventional therapy
and reported success with the use of this drug as second line
treatment, with the dosage of 1g every 12 hours [13]. In our
experience the use of a lower dose mycophenolate mofetil
regimen turned out to be insuﬃcient, as in this patient only
the dosage of 1g every 12 hours induced remission of the
pulmonary haemorrhage.
Although the scientiﬁc value of a single case could be
questionable, randomised trials are almost impossible to
conduct in such a rare disease. Based on the high mortalityInternational Journal of Nephrology 3
and current insuﬃcient therapeutic weapons, in our opinion
mycophenolate mofetil should be considered an alternative
treatment, mainly in relapsing disease.
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